This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Shane Hegarty
Chief Scientific Officer and Co-Founder at Axonis Therapeutics

Profile

Dr. Shane Hegarty is Chief Scientific Officer, Co-Founder and IP Co-Inventor at AXONIS Therapeutics, a Boston-based biotechnology company. He has >12 years’ experience leading cutting-edge, award-winning neuro-protection, -modulation and -regeneration research for neurological disorders. As a Research Fellow in Professor Zhigang He’s lab in Boston Children’s Hospital and Harvard Medical School, Dr. Hegarty led a genome-wide AAV-CRISPR screen for neuro-protection and -regeneration in vivo. Before moving to US, he was Faculty Member in Neuroscience Department of University College Cork, Ireland, and received prestigious Neuroscience Ireland Investigator Award in 2016. A highly productive researcher with 29 research papers (22 as first/senior author), >1,000 citations and h-index = 15, and serial grant awardee. Dr. Hegarty acts as Editor for Frontiers and The Biochemist, and expert reviewer for a number of esteemed journals and international funding agencies. An experienced university lecturer, research supervisor and mentor, who graduated top of his Neuroscience BSc class.

Agenda Sessions

  • Behind the Scenes—Life before the Clinical Trial

    1:50pm